Drug: Pembrolizumab (Keytruda, Merck)
Status: Granted regular approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Granted accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing